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Abstract
Infant sibling studies have been at the vanguard of autism spectrum disorders (ASD) research over the past
decade, providing important new knowledge about the earliest emerging signs of ASD and expanding our
understanding of the developmental course of this complex disorder. Studies focused on siblings of children with
ASD also have unrealized potential for contributing to ASD etiologic research. Moving targeted time of enrollment
back from infancy toward conception creates tremendous opportunities for optimally studying risk factors and risk
biomarkers during the pre-, peri- and neonatal periods. By doing so, a traditional sibling study, which already
incorporates close developmental follow-up of at-risk infants through the third year of life, is essentially
reconfigured as an enriched-risk pregnancy cohort study. This review considers the enriched-risk pregnancy cohort
approach of studying infant siblings in the context of current thinking on ASD etiologic mechanisms. It then
discusses the key features of this approach and provides a description of the design and implementation strategy
of one major ASD enriched-risk pregnancy cohort study: the Early Autism Risk Longitudinal Investigation (EARLI).
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Introduction
In 1957, Pearson and Kley published a prescient paper
asserting that neuropsychiatric research should capitalize
on the “tendency of particular abnormalities of behavior
to run in families” (p. 406) so that “subpopulations
defined in terms of genetic relationship to index cases...
might be studied longitudinally...” (p. 418) [1]. They
went on to note that such studies could be effective and
economical for etiologic research. A 1976 review of the
genetics of infantile autism and childhood schizophrenia
[2] highlighted the potential of Pearson and Kley’s high-
risk design for etiologic research, but at that time the
only such studies underway were investigations focusing
on children of parents with schizophrenia (reviewed by
Garmezy [3]). In the 1980s, prompted by the 1977 pub-
lication of Folstein and Rutter’s seminal autism twin
study [4], siblings of autism probands increasingly were
included in research samples; however, these were lar-
gely cross-sectional family studies in which researchers
looked at recurrence risk and genetic segregation or
linkage, not at prospective investigations where at-risk
siblings were the subjects of principal interest. The first
consideration of the prospective infant sibling study in
autism, according to Yirmiya and Ozonoff, occurred in
the mid-1980s, when US and UK researchers contem-
plated but rejected the idea because of concerns over
heterogeneity in index proband diagnosis [5]. Once stan-
dard diagnostic tools were developed in the early 1990s,
these projects moved forward with a focus firmly on
phenotypic antecedents and very early signs of autism
spectrum disorders (ASDs). Rogers [6] has since
described the discovery of “the first behavioral charac-
teristics that predict development of autism” as the
“Holy Grail” (p. 126) of autism infant siblings research.
Today there are 25 infant sibling research teams that
are part of the High Risk Baby Siblings Research Con-
sortium (BSRC) (Autism Speaks, Research on High Risk
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Baby Sibs: http://www.autismspeaks.org/science/initia-
tives/high-risk-baby-sibs), a voluntary network of pro-
jects with funding support from the National Institutes
of Health and Autism Speaks, united in their common
purpose of pursuing early phenotypic predictors of aut-
ism. The first papers derived from these efforts began to
appear in 2005 and 2006 [7-10], and findings on emer-
gence and trajectory of a range of developmental out-
comes in high-risk infant sibling cohorts have been
published steadily in the literature ever since.
Although discovering robust early phenotypic markers
for autism to facilitate early detection and intervention
remains a major autism research goal and an appropriate
priority for infant sibling studies, the application of the
high-risk infant sibling study design in autism etiology
research has been underexplored. In this paper, we con-
sider the role that infant sibling designs can play in autism
risk factor research in the context of the evolving under-
standing of autism etiology and describe the design and
methods which are being employed by a major high-risk
sibling cohort study focused on autism etiology: the Early
Autism Risk Longitudinal Investigation (EARLI).
Current thinking on etiologic mechanisms in autism
For decades, multiple lines of evidence have supported a
substantial heritable component of autism etiology, includ-
ing twin studies [4,11-14], familial risk studies [15-24], seg-
regation analyses [24-27] and reported correlations
between autism phenotypes and other congenital genetic
disorders [28-32]. Modern genomic methods applied
extensively to a variety of autism samples over the past
decade have underscored the complexity of autism inheri-
tance. A number of rare variants, for the most part de
novo or inherited copy number variations (CNVs) [33-35],
have been linked to autism by virtue of their apparent
high penetrance. The teams leading three major autism
genomewide association studies (GWASs) [33,36,37] have
generated additional candidate genes, but have failed to
replicate each other’s findings. Consequently, lists of plau-
sible autism candidate genes now include well over 100
genes [38,39], including common genetic variants likely to
have very small independent effects but potentially contri-
buting to mechanisms with larger effects by interacting
with each other or with rare genetic events [40]. There-
fore, ongoing efforts are focused on the use of sophisti-
cated analytic techniques applied to genomic data to
identify common, biologically plausible pathways along
which gene-gene interactions may take place [41-44].
In addition to an emphasis on gene-gene interactions,
nearly all recent comprehensive reviews of autism genet-
ics have cited interplay between genetic mechanisms and
environmental exposures as another plausible contribu-
tor to the complexity of autism etiology [45-52]. The
recent twin study conducted by Hallmayer et al. [53],
which was larger than all its predecessors and the first
done with autism cases confirmed using today’s diagnos-
tic tools, suggested a far larger role for environmental
factors than did any earlier twin study. Furthermore, the
fact that dizygotic twin concordance in their study was
substantially larger than nontwin sibling recurrence risk
reported in a recent large study of infant siblings [54]
points to the prenatal period specifically as a period of
special interest with respect to environmental influences.
A potential role for epigenetic mechanisms in autism
etiology [55,56] also suggests additional ways in which
environmental exposures can work in concert with geno-
mic factors [57]. The need to move forward with more
extensive investigation of environmental risk factors in
autism is now widely accepted.
For most of the past 40 years, the investigation of envir-
onmental exposures has been sporadic. Several studies
have provided evidence of highly elevated risk arising from
congenital exposure to rubella [58,59] and cytomegalo-
virus [60]. Similarly, some pharmacologic exposures in the
prenatal period have been linked to autism, including tha-
lidomide [61] and valproic acid [62-64]. More recent epi-
demiologic research has underscored the prenatal period
as the most relevant etiologic window for autism environ-
mental risk factors. For example, large studies have contin-
ued to find associations of autism risk with prenatal
medication use [65,66] and infection [67]. Consistent with
the infection finding, investigators in a small case-control
study who capitalized on banked midpregnancy blood
samples reported more frequent elevations in certain cir-
culating inflammatory cytokines in mothers of children
with autism than controls [68]. The first system-level ana-
lysis of the ASD brain transcriptome, in addition to an
expected finding of synaptic dysfunction, has also sug-
gested the presence of immune dysregulation [69], which
is consistent with an earlier finding of neuroinflammation
in the brains of individuals with autism [70]. However,
whether these indications derived from autopsy studies
reflect antecedent and potentially causal immune-
mediated events or downstream responses to other autism
neuropathology is not yet clear.
Recently published systematic reviews of traditional
obstetric and neonatal risk factors and autism reported
that, for most of the individual risk factors considered
(for example, contraception prior to pregnancy, maternal
obstetric history, bleeding in pregnancy, gestational dia-
betes), either insufficient data were available or findings
have not been well-replicated in the published literature
[71-73]. This is not entirely unexpected, as many past
studies have been based on small clinical samples without
confirmation of diagnoses. However, the one factor with
the most consistent association with increased autism
risk across multiple studies is advanced parental age
[74-80]. A variety of mechanisms might explain these
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associations, such as increased maternal complications
during pregnancy or delivery, an accumulation of toxins
affecting either the intrauterine environment or sperm
development, and induced de novo mutation, of particu-
lar interest in the case of older fathers.
An interesting obstetric risk factor examined only
recently with respect to autism is interpregnancy inter-
val. An interval of less than one year between pregnan-
cies was found in an initial report to be associated with
more than a threefold increase in autism risk compared
to intervals of three or more years (OR = 3.4, 95% CI =
3.00 to 3.82). If short interpregnancy interval is an aut-
ism risk factor, it could implicate the intrauterine envir-
onment through nutritional depletion mechanisms [81].
Indeed, researchers in a large case-control investigation
have reported intake of prenatal vitamin supplements in
the periconception period (three months prior and one
month after conception) to confer nearly a 40% reduc-
tion in risk (OR = 0.62, 95% CI = 0.42 to 0.93) [82].
This study was also notable because it contains the only
published results to date explicitly supporting a gene-
environment interaction in autism with the apparent
protection from maternal prenatal vitamin use magnified
in the presence of certain genotypes involved in one-
carbon metabolism [82].
Several investigations have examined air pollution, a
complex mixture of exposures with wide-ranging toxici-
ties, in relation to autism diagnoses. The designs of
these ranged from a purely ecologic design that focused
on industrial emissions of a single pollutant [83], to
investigations that utilized individual-level diagnostic
information in relation to modeled estimates of 25
hazardous air pollutants [84,85], to distance to freeway,
a strong indicator of ambient traffic-related pollutant
levels [86]. This most recent study, a case-control design
using clinically confirmed cases and individual-level
exposure information, found living within one-quarter
mile of a freeway at the time of delivery was associated
with a 1.9-fold increased ASD risk (95% CI = 1.04 to
3.45). Researchers in earlier studies had used exposures
occurring in the second year of life or later, which
might not be the most etiologically relevant period.
Investigators in a number of other studies have also
explored potential associations between autism diagnosis
or autism-related phenotypes and pesticide exposure in
the prenatal period. Residence in a location where appli-
cation of organochlorine pesticides reached levels falling
into the highest nonzero quartile during the eight-week
pregnancy period after closure of the cranial neural tube
was associated with a sixfold higher odds ratio of the
child’s developing autism (OR = 6.1, 95% CI = 2.4 to
15.3) [87]. In a cohort study of primarily Mexican-
American women, higher levels of metabolites for orga-
nophosphate pesticides were found to predict higher
scores on an autism-related scale in 24-month-olds [88].
Studies attempting to replicate these findings are
needed, though both types of compounds are plausibly
linked to altered central nervous system development
through endocrine disruption for the long-lasting orga-
nochlorines and through direct toxicity to the develop-
ing brain for the rapidly cleared organophosphates.
Other commonly used pesticides have been associated
with general neurodevelopmental deficits in prospective
pregnancy cohorts [89-91] but have yet to be studied in
autism.
With epidemiologic evidence consistently pointing to
the prenatal period as a window of vulnerability to
environmental exposures in autism, one might ask
whether this is consistent with known autism neuro-
pathology. Indeed, pathologic changes documented in
autopsied brains of individuals with autism, including
those found in the brainstem [92], cerebellum [93,94]
and cortex [95], are indicative of a pathologic process
originating in utero. Early brain overgrowth in autism,
now documented in two longitudinal brain imaging stu-
dies [96,97], also suggests the presence of causal events
occurring prior to birth, as does the recent brain tran-
scriptomics report that autism brains lacked a pattern of
differential gene expression across frontal and temporal
cortical regions [69] that typically emerges during fetal
development [98].
Could prenatal causal events be linked to exogenous
exposures? It has long been established that prenatal brain
development, including the fundamental processes of neu-
ronal proliferation, migration, differentiation, synaptogen-
esis, gliogenesis, myelination and apoptosis, are susceptible
to disruption by environmental exposures [99,100]. Subse-
quently, each of these fundamental processes has been
considered in alternative models of autism pathology
[101]. Some of the more recent work geared toward using
autism genomics to identify biologic pathways has impli-
cated synaptic homeostasis as a candidate common biolo-
gical process in autism [102]. Although synapse formation
begins in the third trimester, with synapse restructuring
and connectivity development continuing well into post-
natal life, animal models have shown that environmental
exposures earlier in pregnancy can lead to impaired post-
natal synaptic activity without obvious signs of disruption
prenatally [103]. In addition, other genomics efforts
focused on pathway detection, one using GWAS data and
the other CNV data, have independently implicated
impaired neuronal projection and axonal guidance [35,44]
as mechanisms of chief interest. These are environmen-
tally sensitive processes beginning early in brain develop-
ment [104,105] that could certainly affect synaptic
functioning downstream. Of course, the high likelihood of
an in utero origin of autism in no way rules out the poten-
tial for etiologic and prognostic influences after birth, but
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the design and implementation of etiologic research
focused on the prenatal period would appear strongly
justified.
Expanding the infant siblings approach to study autism
etiology
Infant sibling cohort studies, as implemented by members
of the BSRC, enroll subjects younger than 18 months of
age (many as young as 6 months of age) and carry out
close longitudinal developmental follow-up, typically
through 3 years of age. The design choice was motivated
in part by expected recurrence rates that were many times
higher than population autism prevalence and in part by
the opportunity to observe early behavioral markers and
better understand the complex early natural history of
ASDs afforded by carefully measuring development pro-
spectively. Both of these considerations are also quite ger-
mane to etiologic research. Yet, to maximally capitalize on
infant sibling designs for etiologic research, it is necessary
to extend cohort enrollment back to a point where the
mother and the developing fetus can be followed prospec-
tively through windows of potential etiologic vulnerability;
in other words, by transforming the design to a high-risk
pregnancy cohort. Each of these three features, increased
event rate, prospective developmental assessment and shift
to a pregnancy cohort design, is each discussed further
below.
Increased event rates
When the BSRC was formed, published estimates for sib-
ling recurrence risk ranged from 2% to 9% [13,15-22,
24,106]. Almost all of these studies considered recurrence
of the more narrow autistic disorder diagnosis among sib-
lings of a proband with autistic disorder, although the one
study of probands and siblings with any autism spectrum
diagnosis reported recurrence within the same range
(5.3%) [106]. In 2011, the BSRC published their first find-
ings on ASD recurrence among 684 siblings of probands
with an ASD followed from at least 18 months until at
least 36 months [54]. In this large, recently ascertained
sample, recurrence was 18.7% (95% CI = 13.3% to 25.5%).
Even with recent population ASD prevalence estimates
approaching 1% [107], this implied 20-fold increase in sib-
ling risk translates into increased numbers of cases in an
enriched-risk sibling cohort, which increases power to
detect associations between risk factors and ASD case sta-
tus. In addition, the presence of higher levels of subthres-
hold impairment in toddler-age siblings of ASD probands
has been documented. For example, Toth et al. [108]
found significant differences in expressive and receptive
language, composite IQ, adaptive behavior and social com-
munication skills when they compared (1) 42 toddler-age
siblings of ASD probands who did not meet ASD criteria
based on the toddler-version Autism Diagnostic Inter-
view-Revised (ADI-R) [109] and the Autism Diagnostic
Observation Schedule (ADOS) [110] to (2) 20 typically
developing toddlers with no ASD family history. This sug-
gests that there is a considerable range of impairment in
the infant sibling cohort which should translate into
increased power for risk factor analyses using dimensional
as opposed to categorical phenotypic outcomes. Last, for
conditions such as ASD where complex genetic mechan-
isms underlie increased baseline risk in the infant sibling
sample, if a risk factor’s effect is amplified by an unknown
genotype or genotypes, the power to detect that risk factor
is affected favorably [111].
Prospective developmental assessment
BSRC studies prospectively evaluate a range of develop-
mental end points, including motor development, repeti-
tive behaviors and abnormal movement patterns, social
and emotional development, and response to joint atten-
tion [6]. The prospective developmental assessment in
infant sibling studies can support etiologic research in two
ways.
First, it allows for careful characterization of autism-
related dimensional phenotypes at early ages. As men-
tioned above, dimensional end points may prove revealing
in ASD etiologic research, and perhaps studying variance
of traits expressed very early in life could be the most
revealing. To date, the dimensional measures used in etio-
logic research have been those developed from assessment
of older children [112-114]. Should measures that are now
being used in BSRC studies such as the Autism Observa-
tion Scale in Infants (AOSI) [115] provide valid early mea-
surement of quantitative traits related to autism, enriched
risk pregnancy cohort studies could incorporate these and
utilize them as continuous end points in risk factor
analyses.
Second, the longitudinal characterization of develop-
ment could lead to the identification of distinct develop-
mental trajectories which might themselves be considered
as outcomes or could be used to stratify cases to test
hypotheses that cases with different developmental trajec-
tories could have distinct sets of risk factors. Landa and
Garrett-Mayer [10] have already examined trajectories
within high-risk siblings on a range of items measured by
the Mullen Scales of Early Learning [116,117] among
those meeting or not meeting research criteria for ASD at
24 months and found generally flatter trajectories in the
group meeting these criteria, although they noted different
patterns in different domains, such as the ASD group’s
deviating at 14 months on fine motor performance. Rozga
et al. [118] reported no differences at six months of age in
joint attention and requesting behaviors between high-risk
siblings who went on to meet criteria for ASD and those
who did not, but they found an emergence of differences
at age 12 months. Another recent report, however, found
head lag at 6 months of age to be predictive of social and
communication impairment in high-risk siblings at age
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36 months [119]. As the size of infant sibling cohorts
grows, BSRC investigative teams will be able to employ
more sophisticated analyses to identify unique develop-
mental trajectories, both within and across groups defined
by whether ASD criteria are met.
Shift to a pregnancy cohort design
The returns from expanding infant sibling research can be
amplified with the shift to a pregnancy cohort design. This
approach allows for the prospective collection of detailed
risk factor data during the critical etiologic windows, as
opposed to retrospective collection that would be neces-
sary if cohorts of siblings enrolled as toddlers were used
for risk factor research. For a number of risk factors of
general interest in the prenatal and neonatal periods, vali-
dation studies have demonstrated superiority of prospec-
tive versus retrospective data collection. For example,
retrospective recall of depressive symptoms in pregnancy
at just six months postpartum compared to prospective
documentation showed only moderate agreement [120].
Recall of prenatal influenza infection symptoms (for exam-
ple, persistent cough and fever) at delivery suggest under-
reporting compared to questionnaires completed between
the 18th and 25th weeks of pregnancy [121]. Furthermore,
there are concerns that parents of affected children will
recall exposures during the prenatal period differently
from parents of unaffected children, a phenomenon docu-
mented for certain exposures with respect to birth defects
outcomes [122].
Certain findings that have begun to emerge regarding
potential environmental risk factors for autism have lim-
itations with respect to exposure measurement that could
be obviated through prospective data collection in an
expanded infant sibling study design. For example, one
study of air pollution used modeled estimates covering the
second year after birth [84]. Although the associations that
were observed could contribute to the development of aut-
ism, exposures in earlier years (for example, during gesta-
tion or the first year after birth) might be of greater
relevance. Other retrospective epidemiologic investigations
have explicitly considered exposure during the prenatal
period but have been limited to maternal residence at the
time of birth as a proxy for exposure. For example, one
retrospective study modeled prenatal exposure to pesticide
based on distance from residence to reported date and
location of agricultural applications of pesticides, but there
was no individual-level measurement of exposure available
[87]. The extent to which modeled exposure reflects actual
exposure is a major question, with factors such as address
changes, time spent at home, wind speed and drift, as well
as absence of data on other exposure sources, contributing
to potential misclassification. In addition, a number of stu-
dies have used administrative and medical databases to
examine maternal prenatal use of medications. These data
sources provide unbiased assessment for case-control
comparisons and can address the relevant time periods,
but they do not include data on over-the-counter medica-
tion use and do not take into account the fact that not all
prescriptions are filled and not all filled prescription medi-
cations are actually taken by the patient. The infant sibling
pregnancy cohort design has the potential to combine self-
report data on actual use of medications with medical
records documentation on prescriptions from all sources.
The shift to a prospective cohort design also creates
opportunities for implementation of cost-effective analytic
strategies. When, for example, laboratory assays need to
be completed on stored biologic specimens to generate
risk factor data, these assays can be done on select sub-
samples from the cohort to conserve resources. Analyses
can be limited to identified cases contrasted to a sample of
noncases selected from the cohort at the time of case
occurrence (incidence-density matched case-control
design), a sample of noncases selected at the end of fol-
low-up (cumulative incidence case-control design) or a
sample of cohort members at baseline (case-cohort
design). Such designs can often achieve close to compar-
able statistical power to analyses of data from the entire
cohort [123]. Furthermore, when data on the full cohort
can be used to inform the sampling of cases and controls
(for example, two-stage or countermatching designs),
additional statistical efficiencies can be achieved [124,125].
Alternatively, subsamples can be selected for more
resource-intensive risk factor data collection (for example,
through biomarkers or medical records abstraction), and
the data derived from these subsamples can be used to
correct measures of association based on risk factor data
available in the full cohort or in case-control samples
drawn from the full cohort [126].
The current thinking on autism etiology, where causal
mechanisms are believed to be complex and multifactor-
ial, is that a role for environmental factors is quite likely.
However, research on environmental risk factors for aut-
ism faces significant challenges. Critical periods may
occur early in brain development, and accurate measure-
ment of environmental exposure during these critical
periods will be important if causal contributions of these
factors in the context of other contributors are to be
identified. Etiologic heterogeneity in autism is likely, and
identification of phenotypic correlates that mark distinct
etiologies or, perhaps more realistically, can serve as use-
ful endophenotypes for identifying certain causal compo-
nents, is an active area of ongoing research. Given this
situation, the expansion of infant sibling study designs
for etiologic research where exposure data are captured
prospectively during potentially relevant critical windows,
outcomes are also prospectively characterized in detail,
and event rates are higher than in population-based sam-
ples would appear to be one quite useful research
approach. The sections that follow provide an overview
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of a large multisite investigation now underway that is
implementing this study design.
The EARLI Study as a model for risk factor research using
a high-risk infant sibling design
The EARLI Study was conceived to capitalize on expand-
ing the infant siblings approach to autism etiologic
research to realize many of the benefits described above.
At least one other autism enriched-risk pregnancy cohort
study that has many features in common with EARLI is
now underway (the Markers of Autism Risk in Babies-
Learning Early Signs (MARBLES) study: http://marbles.
ucdavis.edu/). Below the EARLI research design, study
population, recruitment and enrollment approach, risk
factor data collection and outcomes evaluation strategy
are described. Other investigators looking to replicate or
incorporate aspects of this approach may benefit from the
information provided herein. The EARLI Study parent
protocol was reviewed and approved by the Drexel Uni-
versity Institutional Review Board (Project no. 71109; Pro-
tocol no. 17862). Local IRB approvals were also obtained
at all EARLI Study sites. All study participants have under-
gone the consent process and signed the relevant consent
or assent forms as appropriate for age and cognitive abil-
ity, or have had a parent consent on their behalf.
Study design
The EARLI Study is a multisite prospective pregnancy
cohort study of mothers of children with an ASD diagno-
sis (autistic disorder, Asperger syndrome or pervasive
developmental disorder not otherwise specified (PDD
NOS)) who have become pregnant. Mothers are followed
through pregnancy and delivery, then the pregnancy
cohort evolves into an infant siblings cohort followed
through age three years. Eligible pregnant women are
enrolled by the 28th week of pregnancy, along with their
biological child who has an ASD (the study proband). The
biological father of the current pregnancy is also invited to
enroll, although his participation is not a requirement for
the participation of the mother and proband. Enrolled
mothers are followed closely with intensive data and bio-
sample collection. During the pregnancy, two to four
study visits occur, which entail collection of serial biologi-
cal samples from the mother and dust samples from the
home. At the time of delivery, placental tissue, cord blood,
heel stick blood and meconium are collected. Serial biolo-
gical samples are collected postpartum from both the
mother and the newborn baby (the study sibling). Clinical
evaluations are conducted four times, beginning at six
months of age and concluding when the child is three
years old. The evaluations include autism and behavioral
assessments and dysmorphology examinations. At the
final study visit when the child is 36 months of age, the
sibling’s ASD status is determined for all participants,
although individual diagnoses may have been made earlier,
depending on when symptoms emerged. Throughout par-
ticipation in the study (prenatally and postdelivery) self-
report data are collected from the mothers by using
EARLI instruments and interviews that cover health beha-
viors, diet, reproductive and medical history, stress,
depression, environmental and occupational exposures
and medication use. Additional data are collected from the
mother about the sibling during the first three years of life
regarding general health, medications and medical care,
specific symptoms or illnesses, diet, environmental expo-
sures and developmental interventions. The EARLI Study
is on pace to enroll 870 families over a 6-year period with
plans in place to acquire follow-up data through 36
months from 630 of these families. Figure 1 shows key ele-
ments in EARLI Study data collection over the course of a
family’s participation
Study population
Women who meet the following criteria are eligible to
participate in the EARLI Study: (1) have a biological
child who has been diagnosed with an ASD, (2) compe-
tent to communicate in English (or, at two sites, in
Spanish), (3) 18 years of age or older, (4) live within two
hours of a study clinic and (5) are no more than 28
weeks pregnant. Women who meet the first four criteria
and are not pregnant but trying to become pregnant or
may become pregnant in the future (for example,
unplanned pregnancy) may be followed and contacted
regularly to ascertain their reproductive status. If they
become pregnant during this preenrollment period, they
can be rescreened for eligibility to enroll.
The EARLI Study is being implemented at four field
sites in three distinct locations in the US, representing a
racially, ethnically, and socioeconomically diverse study
population (Table 1). The sites are based in major
metropolitan areas (that is, Philadelphia, Baltimore, San
Francisco Bay Area, and Sacramento) and catchment
areas expand to a 2-hour radius of the study clinic at
each site. Table 1 lists the range of county level demo-
graphics within the catchment areas.
Participant recruitment
Recruitment strategies vary by field site to accommodate
the unique resources available to each site. Generally,
the target population is mothers with a young child (2
to 12 years old) with ASD, who would be more likely to
become pregnant again than a mother with an older
child. For example, for the Pennsylvania and Maryland
sites, a primary strategy for reaching potentially eligible
mothers is distribution of information through the early
intervention and special education systems. The north-
ern California site at the University of California, Davis,
identifies and reaches potentially eligible mothers pri-
marily through the state’s Department of Developmental
Services, whereas the Kaiser Permanente site in north-
ern California can identify Kaiser Permanente members
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who become newly pregnant and already have children
with autism. Clinical service providers in the catchment
areas, including ASD evaluation and diagnostic centers,
developmental pediatricians and mental health service
providers, are also engaged at each site to reach poten-
tially eligible women. The researchers in the EARLI
Study have not focused on establishing relationships
with providers serving the general population of preg-
nant women (for example, obstetricians, nurse mid-
wives) or children (for example, general pediatricians)
for individual-level outreach but will make available gen-
eral information about the EARLI Study as requested.
All field sites carry out supplementary recruitment
efforts through staffed information tables at autism
events and through advocacy organizations’ websites,
listservs and newsletters. Reinforcing information about
the EARLI Study through multiple channels increases
the chance that mothers of reproductive age who have
children with ASD, at a later time when they are preg-
nant, will remember and consider enrolling in the
EARLI Study. To that end, EARLI also maintains an
active presence in social media, including Facebook
[127] and YouTube [128] and has a web presence [129]
that includes content geared toward potentially eligible
mothers as well as enrolled participants. Given this
recruitment approach, it is possible that participating
families might differ from their respective area source
population on factors related to the extent of connection
to service systems and the degree of immersion in the
autism community. To introduce bias, such selection
needs to be differential with respect to both exposure
and outcome. Although these selection effects could be
associated with certain exposure profiles of interest,
independent associations with ASD risk, though concei-
vable, seem less likely. EARLI Study sites, to varying
degrees, will be able to explore differences between par-
ticipating families and source populations. All sites can
compare basic characteristics of participating families
with families in the region receiving services for a young
child with ASD, but only the Kaiser Permanente site has
the ability to identify the subgroup in the source popula-
tion who are becoming pregnant.
Enrollment and retention
When a pregnant mother of a child with autism begins
the enrollment process, proband diagnosis first needs to
be confirmed. In families with more than one child with
Figure 1 Early Autism Risk Longitudinal Investigation Study data collection points over the course of participation.
Table 1 Range of the percentage of demographic characteristics among the counties in EARLI Study field site areasa
County Low and High Percentages within Field Site Catchment Areas






White 41.0% to 89.2% 19.2% to 92.9% 43.0% to 91.4%
Black or African-American 3.6% to 43.4% 3.2% to 64.5% 0.4% to 14.7%
Asian 0.8% to 8.9% 1.1% to 14.4% 1.1% to 33.3%
Hispanic or Latino 3.0% to 18.8% 2.6% to 17.0% 8.5% to 55.4%
Language other than English spoken at home (5 years
or older)b
7.4% to 24.8% 5.2% to 35.8% 6.5% to 51.2%
Families below povertyc 4.2% to 22.9% 4.5% to 22.9% 7.2% to 24.6%
25+ years old with educational attainment 9th to 12th
grade, no diploma†
7.8% to 28.8% 5.7% to 31.6% 6.6% to 33.0%
aData are derived from the 2010 US census. b2005 to 2009 for all counties; 2000 for Philadelphia City and Baltimore City. c2009 for all counties; 1999 for
Philadelphia City and Baltimore City. EARLI, Early Autism Risk Longitudinal Investigation.
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ASD, the study proband is the child who is the closest
biologic relation to the future sibling, or, if both are the
same biologic relation to the future sibling, then a child
with an autistic disorder diagnosis would be enrolled
over a child with Asperger syndrome or PDD NOS. The
mother is enrolled in the study after consenting at the
enrollment clinic visit, and the study proband’s eligibility
is confirmed by a valid ADOS [109] and an age-appro-
priate IQ test (for example, Mullen Scales of Early
Learning for infancy to 68 months of age; or the Kauf-
man Brief Intelligence Test, Second Edition, for ages 4
years to 90 years). Fathers may enroll at the enrollment
clinic visit, or during a home visit if they are not at the
enrollment clinic visit.
As Figure 1 illustrates, the EARLI Study involves exten-
sive data collection, so investigators strive to maximize
retention by being as flexible as possible. Both online and
paper versions of most questionnaires and documents are
available, and home visits and flexible visit scheduling is
accommodated when possible. Of the first 177 families
enrolled in the study, 97.2% are still participating. Variabil-
ity in the time of data collection creates challenges and
opportunities for research but is also a reality of intensive,
prospective follow-up of this study population. Retention
in the EARLI Study is also driven by the prospective devel-
opmental follow-up offered for the at-risk siblings. EARLI
Study sites provide families with summaries of research
evaluations, discuss questions with families, provide infor-
mation on local resources for families concerned with
their child’s development and make referrals for services
for affected siblings. Upon enrollment, the EARLI Study
also provides families with a specially developed social
storybook about the impending arrival of a baby sibling
that parents can use in interactions with the proband.
EARLI Study investigators stay connected with enrolled
families as a group through the study website, Facebook
and study newsletters.
Risk factor data collection
The EARLI Study approach to risk factor data collection is
comprehensive, involving multimodal self-report, records
review, direct observation and biologic and environmental
sample collection. This approach allows for analysis of risk
factor characterization during specific suspected etiologic
windows, comparison of risk factor data from multiple
sources, estimation of risk factor-outcome associations
motivated by specific hypotheses and discovery-oriented
work intended to reveal first evidence for novel risk fac-
tors. Table 2 provides a broad overview of data collection
modes by subject. Self-reports are provided by both par-
ents at enrollment and extend back to the preconception
period. During pregnancy, mothers provide reports in
weekly pregnancy diaries regarding exposures that are
more challenging to recall retrospectively and are exten-
sively interviewed twice (approximately 625 items) to col-
lect information retrospectively on less time-sensitive
information in pregnancy. Selected self-report question-
naires are also used to cover specific domains such as diet
and depressive symptoms. Table 3 summarizes the range
of risk factor domains covered by EARLI Study self-report
data collection.
Biosampling in the EARLI Study is comparably exten-
sive. Fathers and probands provide biosamples at enroll-
ment. Venous blood is collected from both, and fathers
are also provided with a home semen collection kit. Bio-
sampling in mothers begins at enrollment with the collec-
tion of blood, first void urine and hair. Mothers provide
these samples at least once and as many as three addi-
tional times during pregnancy, depending on how early in
the pregnancy enrollment occurred. The EARLI Study
makes efforts to work closely with mothers, obstetricians
and/or birth hospitals to facilitate the collection of delivery
samples. Umbilical cord blood and placental samples are
collected as close to delivery as possible. Four placental
punch biopsies, two from the maternal and two from the
fetal side, are taken and placed into cryovials of RNAla-
ter™ (QIAGEN, Valencia, CA, USA). The remaining pla-
cental tissue is fixed in formalin. Heel stick cards are left
at the hospital, and newborn blood is collected by hospital
staff after neonatal screening whenever possible without
an additional heel stick. Mothers are provided with collec-
tion kits for breast milk, meconium and diaper urine.
Manually expressed breast milk is collected at one week
Table 2 EARLI Study data collection modes by subjecta
Mother
Data collection mode Preconception Prenatal Perinatal Father Proband Sibling
Self-report retrospective X X X X X
Self-report prospective X X
Biologic sampling X X X X X
Direct observation (home environment) X X
Environmental sampling X X
Medical recordsa X X X X X X
aThe EARLI Study secures medical record releases for each participant and will pursue abstraction as needed to support individual analyses. EARLI, Early Autism
Risk Longitudinal Investigation.
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(postcolostrum) and twelve weeks. Nighttime diaper urine
is collected from a sterile gauze pad at one week. Study
staff visit the family at three months and pick up biologic
samples the family has retained in the home freezer and
also collect clean-catch urine from the infant sibling at
that time. At the six-month clinic visit, mothers again pro-
vide blood, urine and hair samples, and a first venous
blood sample, another diaper urine sample and a hair sam-
ple are taken from the infant sibling. Biosampling con-
cludes with infant siblings’ providing venous blood and
diaper/pull-up pad urine samples during the 12- and 24-
month follow-up clinic visits. This continued longitudinal
sampling of blood and urine in siblings provides opportu-
nities for assessment of early life exposures and also cre-
ates the potential to investigate peripheral biomarkers of
early outcome. Biosampling time points by participant and
sample type are summarized in Table 4.
Biosample-processing decisions in EARLI were made
by balancing timeliness, logistics and cost while being
mindful of the nature of each sample. Processing on-site
is minimal for venous blood, limited to centrifuging as
dictated by tube type, with samples shipped next-day
delivery to the central laboratory and biorepository
(CLBR). The complement of tube types used varies
slightly by subject and visit, but generally ethylenediami-
netetraacetic acid (EDTA) and serum separator tubes
(SSTs) are used during each draw with the PAXgene
Blood RNA Kit (QIAGEN, Valencia, CA, USA), pre-
screened metal EDTA and cell preparation tubes (CPTs)
interspersed. Maternal first void and infant sibling urine
are aliquoted and frozen on-site and shipped monthly on
dry ice to the CLBR. Diaper pad urine, meconium and
breast milk are also batch-shipped frozen to the CLBR.
Semen samples are collected by the father and frozen at
home for a minimum of 24 hours, then shipped directly
to the CLBR. Dried heel stick cards are sent back to the
sites, where they are stored at ambient temperature and
batch-shipped, as are hair samples, to the CLBR. Blood
sample processing at the CLBR generates a repository of
multiple aliquots of stored plasma, serum, whole blood,
extracted DNA and peripheral blood mononuclear cells
(PBMCs), including aliquots processed and saved to
allow for establishment of cell lines.
Researchers in the EARLI Study also assess the home
environment once during pregnancy and at the three-
month postpartum home visit. The home assessment
includes a walk-through survey with questions related to
how the family distributes their indoor time across
rooms in the home, characteristics of the principal
rooms where the mother and infant sibling spend most
Table 3 Domains of risk factor data collected from
interviews, diaries and other self-report forms
Risk factor domains Interviews Diaries Other self-report
formsa
Demographics M, F F
Medication exposure M, F M, S M, F, S
Medical conditions M M M, F, S
Pesticides S M, S
Diet M S M
Home environmental
exposures
M M, S M, F
Health behaviors/lifestyle S M, F
Mental condition/history/
symptoms
M M M, F, S
Vaccine history M, S
Personal product use M M, S M
Anthropometrics M M M
Medical procedures M M, S M, F
Occupational history M, F
aIncludes the following forms: Home Walkthrough Survey, Maternal Interview
Update, CHARGE Family Medical History Form, Dietary History Questionnaires
(preconception, 1 to 20 weeks, 21 to 36 weeks and postnatal), Health
Behaviors Questionnaires (preconception, pregnancy and paternal), Paternal
Interview, 24-Hour Recalls (food and environment), Stress and Depression
Surveys, Postnatal Diaries, Blood Draw Information Form, Maternal Medical
History, Post-Partum Environmental Exposures and Dust Field Log. M, mother;
F, father; S, sibling.
Table 4 EARLI biosampling time points by biosample and participant typea
Sample Mother Father Proband Infant sibling
Blood E, pre-2nd, pre-3rd, post-6
months
E E Post-6 months, post-12 months, post-24 months
Hair E, pre-2nd, pre-3rd, post-6
months
Post-6 months, post-12 months, post-24 months
Urine E, pre-2nd, pre-3rd, post-6
months
Post-1 week, post-3 months, post-6 months, post-12 months, post-24
months
Semen E




Breast milk Post-1 week, post-3 months
aD, delivery; E, enrollment; EARLI, Early Autism Risk Longitudinal Investigation; pre-2nd, second prenatal visit; pre-3rd, third prenatal visit; post-1 week, 1 week
postnatal; post-3 months, 3 months postnatal; post-6 months, 6 months postnatal; post-12 months, 12 months postnatal; post-24 months, 24 months postnatal.
Newschaffer et al. Journal of Neurodevelopmental Disorders 2012, 4:7
http://www.jneurodevdisorders.com/content/4/1/7
Page 9 of 16
of their time, cleaning product use, and indoor and out-
door spray and pesticide use. A dust sample is also col-
lected from the main living area by using a Eureka
Mighty Mite vacuum cleaner (Eureka Co, Charlotte, NC,
USA) following a protocol used in multiple previous
studies [130-134]. House dust is an easily collected
reservoir comprising compounds such as pesticides,
plasticizers and flame retardants and has served as a
marker of exposure in several epidemiologic studies
[135-139].
Finally, the members of the EARLI Study team obtain
medical record release forms from all participants, and
they plan to abstract records as needed to assess expo-
sure related to clinical domains where self-report data
have inherent limitations and/or where medical records
data might validate recall. Items of particular interest
include specific clinical tests or results in mothers (for
example, type of ultrasound, blood pressure, blood glu-
cose levels) and newborns (for example, oxygen satura-
tion values, fetal heart rate tracings, newborn screening
results) and details regarding indications and dates for
procedures and medications.
Outcome data collection
Infant siblings are followed to age 36 months, with clini-
cal assessment of ASD-related behaviors and other
developmental domains occurring at 6, 12, 18, 24 and
36 months. Behavioral outcome assessment tools are
summarized in Table 5. The assessment protocol was
designed to measure core autism and related pheno-
types, enabling investigation of dichotomous end points,
continuous outcomes and developmental trajectories.
Direct observation, interview and parent-report mea-
sures are all used. The autism-specific direct observation
tool used at ages 6 and 12 months is the AOSI [115].
Initial evaluation of this tool suggested that total scores
are the most robust predictor of autism at 24 months of
age [115], and work is ongoing to assess the dimensional
measure utility of the AOSI as well as the predictive
ability of both total score and specific items [140]. At
ages 24 and 36 months, the ADOS is administered. At
these ages, the ADOS has high sensitivity for both aut-
ism and ASD, along with moderate specificity, using the
revised scoring algorithm [141]. An algorithm has also
recently been developed for converting raw ADOS
scores to a 10-point severity measure (with scoring also
dependent on ADOS module, classification and age)
[142]. At 36 months, the ADI-R is also administered.
The addition of the ADI-R to ADOS results for deter-
mining a final classification markedly improves classifi-
cation specificity without major sacrifices in sensitivity
[141]. The Social Responsiveness Scale (SRS) [143,144]
has been shown to have useful dimensional scale prop-
erties in first-degree relatives of affected probands
[145,146]. The EARLI researchers administer the Pre-
school Version (for 3-year-olds) of the SRS to infant sib-
lings at age 36 months. At enrollment, the Adult












AOSI (Autism Observation Scale for Infants) X X
ADI-R (Autism Diagnostic Interview-
Revised)
X
ADOS (Autism Diagnostic Observation
Schedule)
X X
SRS (Social Responsiveness Scale) X
Other behavioral assessments
CSBS-DP (Communication and Symbolic
Behavior Scales Developmental Profile)
Infant/Toddler Checklist
X X X





M-CHAT(Modified Checklist for Autism in
Toddlers)
X X
Mullen Scales of Early Learning X X X X
Rothbart Temperament Questionnaires X X
SEQ (Sensory Experiences Questionnaire) X X X
Vineland II
(Vineland Adaptive Behavior Scales, 2nd
edition)
X X X X X
aEARLI, Early Autism Risk Longitudinal Investigation.
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Research Version of the SRS is administered to the par-
ents, who each report on their spouse, and the Pre-
school Version or the Autoscore Form Parent Report is
administered to the proband, depending on the pro-
band’s age.
In addition, EARLI incorporates other behavioral mea-
sures that have been demonstrated to have value in phe-
notyping high-risk infant siblings. The Mullen Scales of
Early Leaning, in addition to providing data on subdo-
mains of particular interest, such as nonverbal IQ [117]
and motor functioning [147], has also been used more
broadly to characterize developmental trajectory in high-
risk siblings [10,148]. The Vineland Adaptive Behavior
Scales [149,150] have been employed effectively with
infant sibling data to differentiate functional phenotypes
[148]. In addition, other tools can improve the richness of
available data on early language and communication
(Communication and Symbolic Behavior Scales Develop-
mental Profile Infant/Toddler Checklist (CSBS DP ITC)
[151,152] and MacArthur-Bates [153,154]), sensory
impairments [155], temperament (Rothbart) [156,157] and
emergent maladaptive behavioral and emotional problems
(Child Behavior Checklist (CBCL) [158,159]).
The EARLI Study also incorporates data collection
regarding physical features and medical comorbidities. At
age 36 months, a dysmorphology assessment is completed
following a protocol adapted from the Study to Explore
Early Development (SEED) [160]. This examination
involves direct measurement of growth parameters
(height, weight, head circumference and body mass index)
and evaluation of dysmorphology. A trained member of
the research team photographs the child’s face and ears
(front of face, right and left profiles of ears, and left and
right three-quarters images showing each ear and the
face), hands (both sides and a hand scan of the palms),
feet (weight-bearing and not), teeth, any skin findings and
two posterior views of the head to identify hair whorl and
hairline. For the facial photographs, a size reference sticker
is included. Parents are queried about the presence of phy-
sical anomalies and whether the child has ever had correc-
tive surgery, has been diagnosed with any syndromes or
has had any genetic testing. This same assessment is admi-
nistered to the proband at the time of enrollment. At the
6-, 12- and 24-month study visits, the sibling also receives
a brief physical examination to capture infant growth para-
meters (length, weight, head circumference and weight-to-
length ratio), and the parents are asked the same set of
questions on genetic testing, anomaly or syndrome diag-
noses and corrective surgeries. Finally, a comprehensive
medical history questionnaire completed by the mother
addresses any medical problems and procedures that have
occurred during the course of the infant sibling’s first
three years of life. As mentioned above, medical records
releases are obtained for the infant sibling to allow follow-
up for more details on any problems or procedures noted.
The design, recruitment strategy and data collection
approach of the EARLI Study are intended to build a data
platform upon which a wide range of prenatal and early
life risk factor investigations will be launched. The rich
combination of prospectively collected exposure and out-
come data should allow for analyses that incorporate
strong confounder control and limit exposure misclassifi-
cation and have a range of data sufficient to approach
complex questions of effect modification and mediation
along risk pathways. Although EARLI’s sample size is large
in relation to other infant sibling studies, there will no
doubt be challenges related to sample size, and, as men-
tioned previously, attention to designing analytic contrasts
in ways that maximize efficiency and incorporation of
dimensional as well as categorical outcomes will likely
prove helpful in this regard.
Conclusions
Infant sibling studies have already played a major role in
autism research over the past decade, improving our
understanding of the complex early developmental trajec-
tory of autism, providing exciting leads on approaches for
early detection and documenting recurrence risk under
today’s diagnostic standards. Extension of the infant sib-
lings design to intervention studies is already underway,
with behavioral interventions being tested in high-risk
siblings with very early signs of developmental issues
(see, for example, the Infant Start Study [161]).
As described above, the potential for the extension of
the design to autism risk factor research is great. The
EARLI Study has substantial potential to contribute to risk
factor research on its own; however, there is also added
potential through collaborations and extensions of the
EARLI project. The EARLI Study team is working with
researchers in the Infant Brain Imaging Study (IBIS) [162],
another extension of the infant siblings design adding pro-
spective brain imaging to developmental follow-up, to
conduct coordinated genomics on both EARLI and IBIS
study samples to undertake pooled analyses of genetic var-
iants and developmental phenotypes. Because both IBIS
and EARLI are collecting phenotype data on infant siblings
longitudinally from ages 6 to 36 months, they have a
unique opportunity to examine genetic relationships with
developmental trajectories in addition to autism per se.
Moreover, the genetic data will support independent ana-
lyses of genotypes and brain imaging in the IBIS sample
and gene-environment interaction in EARLI. EARLI has
also partnered with experts in epigenetics to explore the
potential role of epigenetic mechanisms in autism and the
possible link between epigenetics and environmental risk
factors. Through a National Institutes of Health Roadmap
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program award, EARLI data will be analyzed in parallel
with data from two other birth cohort studies to examine
relationships between DNA methylation (DNAm) and
prenatal exposures, as well as between DNAm, birth out-
comes and early childhood developmental milestones. As
the EARLI cohort develops, other opportunities to take
advantage of the rich available data in this unique sample
are sure to arise.
Last, in addition to enriched risk pregnancy cohorts
such as EARLI, it should be noted that worldwide there
are several population-based pregnancy cohort studies, in
which recruitment is not geared to enriched-risk families,
that have made autism an identified outcome of interest
[163-167]. These studies range in size from the 1,200-
subject Hamamatsu Birth Cohort in Japan [168] to the
110,000-subject Autism Birth Cohort Study [167] that
has recently been incorporated into the Norwegian
Mothers and Babies Study [169]. Researchers in popula-
tion-based cohort studies can explore the generalizability
of findings that emerge from enriched-risk designs and
could also become engaged with enriched-risk cohorts in
coordinated analytic efforts to study rare prenatal expo-
sures or complex etiologic mechanisms.
As research on autism risk factors and risk biomarkers
during the pre-, peri- and neonatal periods intensifies
during the coming decade, enriched-risk cohort designs,
along with large case-control studies [170,171] and popu-
lation-based cohort designs, can be expected to play an
important role. This expansion of autism infant sibling
studies, which have emerged during the past five years as
extremely valuable tools with which to improve under-
standing of the early-life autism phenotype, to address
etiologic questions will, we hope, mark an important step
toward identification of avoidable or modifiable factors
that will ultimately help reduce the population morbidity
and impact of autism on quality of life.
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